BATM appointed Eran Zahavy as CEO of ADOR Diagnostics, an associate that is developing the NATlab rapid molecular diagnostics platform.
Zahavy has more than 20 years' experience in leading positions in government and private bio-science organisations, including R&D manager for biological pathogens diagnostics and Head of Innovation at the Israel Institute for Biological Research (IIBR).
During the pandemic he oversaw the development of the BriLife COVID-19 vaccine at IIBR in collaboration with US-based NRx Pharmaceuticals.
Recently, Zahavy served as CTO of the Group's Bio-Medical Division and as Senior Scientific Consultant to ADOR and BATM's Adaltis diagnostics subsidiary.
"We're pleased to have appointed Eran as CEO of ADOR," Zvi Marom, BATM's chief executive, said. "He has an impressive track record of bioscience development and has been critical to the fantastic progress that we have made in our Bio-Medical Division in recent years
"It is an exciting time for ADOR as we move to the pre-production phase and towards becoming a commercial clinical solution.